Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | DRD3 | P35462 | 8/20 | 0.45 |
| ▸ | HTR6 | P50406 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626519 | 0.87 | KDM2B (0.51) | HTR6 | |
| SCHEMBL21159016 | 0.83 | MMP1 (0.54) | CYP2D6HTR6TSHR | |
| SCHEMBL22812232 | 0.83 | TSHR (0.60) | MAPTNPSR1CYP2D6CYP3A4USP2 | |
| SCHEMBL20148744 | 0.79 | CYP2D6 (0.47) | MAPTNPSR1CYP2D6CYP3A4USP2 | |
| SCHEMBL20626520 | 0.77 | MAPT (0.43) | MAPTNPSR1CYP2D6CYP3A4USP2 | |
| SCHEMBL22031245 | 0.76 | RET (0.49) | CYP2D6TSHR | |
| SCHEMBL685172 | 0.74 | POLB (0.67) | MAPTCYP2D6HRH3DRD3HTR6 | |
| SCHEMBL21540450 | 0.71 | MAPT (0.53) | MAPTNPSR1CYP2D6CYP3A4USP2 | |
| SCHEMBL1000444 | 0.70 | MAPT (0.64) | MAPTNPSR1CYP2D6CYP3A4USP2 | |
| SCHEMBL20154516 | 0.70 | KMT2A (0.50) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | MAPT 1769/4885NPSR1 2516/4885CYP2D6 3706/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MAPT 1769/4885NPSR1 2516/4885CYP2D6 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.